Jay S. Duker - 01 Nov 2021 Form 3 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Operating Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
01 Nov 2021
Net transactions value
$0
Form type
3
Filing time
03 Nov 2021, 17:48:01 UTC
Next filing
11 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EYPT Common Stock 5,657 01 Nov 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EYPT Employee Stock Option (right to buy) 01 Nov 2021 Common Stock 4,000 $31.70 Direct F1
holding EYPT Employee Stock Option (right to buy) 01 Nov 2021 Common Stock 4,000 $26.50 Direct F2
holding EYPT Employee Stock Option (right to buy) 01 Nov 2021 Common Stock 2,666 $19.50 Direct F3
holding EYPT Employee Stock Option (right to buy) 01 Nov 2021 Common Stock 60,300 $13.13 Direct F4
holding EYPT Employee Stock Option (right to buy) 01 Nov 2021 Common Stock 3,350 $12.90 Direct F5
holding EYPT Employee Stock Option (right to buy) 01 Nov 2021 Common Stock 25,000 $7.20 Direct F6
holding EYPT Restricted Stock Units 01 Nov 2021 Common Stock 14,900 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option became fully exercisable on 12/12/2019
F2 This option became fully exercisable on 2/21/2020
F3 This option became fully exercisable on 6/21/2019.
F4 The option to purchase will vest and become exercisable over a four year period as follows: 25% on 2/9/2022 and then ratably over the remaining thirty-six months
F5 This option became fully exercisable on 2/28/2021
F6 The option to purchase will vest and become exercisable as follows: 25% at 7/13/2021 and the remainder ratably, on a monthly basis, over the remaining three years.
F7 The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.